AEON Biopharma’s CMO Buys 862,500 Shares at Zero Cost, Signaling Bullish Confidence in Neurotoxin Pipeline
Insider buying at AEON Biopharma signals confidence in its neurotoxin pipeline, hinting at future upside and urging investors to watch clinical milestones.
3 minutes to read
